Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003324318 | SCV004030093 | pathogenic | Severe combined immunodeficiency disease | 2023-07-12 | criteria provided, single submitter | clinical testing | Variant summary: JAK3 c.2141C>T (p.Thr714Met) results in a non-conservative amino acid change located in the Protein kinase domain (IPR000719) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.4e-05 in 251400 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in JAK3 causing Severe Combined Immunodeficiency (4.4e-05 vs 0.00094), allowing no conclusion about variant significance. c.2141C>T has been reported in the literature in multiple homozygous individuals affected with Severe Combined Immunodeficiency (Nair_2018, Tezcan_2005). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 30293248, 15644840). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. |
Fulgent Genetics, |
RCV005029981 | SCV005655169 | pathogenic | T-B+ severe combined immunodeficiency due to JAK3 deficiency | 2024-04-11 | criteria provided, single submitter | clinical testing |